Nephrogenic systemic fibrosis: A serious adverse reaction to gadolinium-1997-2006-2016. Part 2

Acta Radiologica

Volumn 57, Issue 6, 2016, Pages 643-648

  Thomsen, Henrik S ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; CONTRAST MEDIUM;

GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LEGAL ASPECT; MORBIDITY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY; ANIMAL; BIOPSY; CHEMICALLY INDUCED; KIDNEY FUNCTION TEST; NEPHROGENIC FIBROSING DERMOPATHY; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; BIOPSY; CONTRAST MEDIA; GADOLINIUM; HUMANS; KIDNEY FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; PREVALENCE; RISK FACTORS;

EID: 84978771892     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1177/0284185115626481     Document Type: Review

References (31)

1. Thomsen HS, Marckmann P. Extracellular Gd-CA: Differences in prevalences of NSF. Eur J Radiol 2008;66: 180-183.
2. Rydahl C, Thomsen HS, Marckman P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a Gadolinium(Gd)-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-144.
3. Todd DJ, Kagan A, Chibnik LB, et al. Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheumat 2007;56:3433-3441.
4. Wertman R, Altun E, Martin DR. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008;248:799-806.
5. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008;66: 230-234.
6. Pirovano G, Munley J, Schultz C, et al. Nephrogenic systemic fibrosis: a review of published cases and results from three prospective observational studies. ECR 2012 Book of Abstracts. Insights Imaging 2012;3(Suppl. 1): S293.
7. Thomsen HS. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 2007;17:2692-2696.
8. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imag 2007; 7:130-137.
9. Kalb RE, Helm TN, Sperry H, et al. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 2008;8: 607-610.
10. Daftari Besheli L, Aran S, Shaqdan K, et al. Current status of nephrogenic systemic fibrosis. Clin Radiol 2014;69:661-668.
11. Thomsen HS. Nephrogenic systemic fibrosis and gadolinium-based contrast media. In: Thomsen HS, Webb JAW (eds) Contrast Media: Safety Issues and ESUR Guidelines, 3rd ed. Heidelberg: Springer, 2014, pp.201-217.
12. Wollanka H, Weidenmaier W, Giersig C. NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 2009;24: 3882-3884.
13. Elmholdt TR, Jørgensen B, Ramsing M, et al. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus 2010;3: 285-287.
14. Collidge T, Thomson P, Mark P, et al. Is this really a true case of NSF following Gadovist exposure alone? Nephrol Dial Transplant 2010;24:1352-1353.
15. Reilly PF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on longterm hemodialysis. Clin J Am Soc Nephrol 2008;3: 747-751.
16. Amet S, Launay-Vacher V, Clément O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents. The Prospective Fibrose Nephrogénique Systémique Study. Invest Radiol 2013;49:109-115.
17. Bennett CL, Qureshi ZP, Sartor AOS, et al. Gadolinium induced nephrogenic systemic fibrosis, the rise and fall of an iatrogenic disease. Clin Kidney J 2012;5:82-88.
18. Thomsen HS. NSF: Still relevant. J Magn Reson Imaging 2014;40:11-12.
19. ESUR Contrast Media Safety Committee. ESUR Guidelines on Contrast Media 9.0. 2014. ESUR Office Vienna.
20. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008;158:273-280.
21. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:27-30.
22. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus GD (HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-278.
23. Abraham JL, Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 2008;66:200-207.
24. Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-3178.
25. Van der Molen AJ. Diagnostic efficacy of gadoliniumbased contrast media. In: Thomsen HS, Webb JAW (eds) Contrast Media: Safety Issues and ESUR Guidelines, 3rd ed. Heidelberg: Springer, 2014, pp.181-191.
26. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. Am J Roentgenol 2007;188:1447-1474.
27. Thomsen HS, Marckmann P, Logager VB. Enhanced computed tomography or magnetic resonance imaging: A choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 2007;48: 593-596.
28. Diego DR. Nephrogenic system fibrosis: a radiologist's practical perspective. Eur J Radiol 2008;66:220-224.
29. Morcos SK, Thomsen HS, Webb JAW. Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) Dialysis and contrast media. Eur Radiol 2002;12:3026-3030.
30. Thomsen HS. Contrast enhanced MRI in patients with impaired renal function: recent recommendations to minimize the risk of nephrogenic systemic fibrosis. Solutions in Contrast Imaging 2010;1:1-8.
31. Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 2006; 16:2619-2621.